Stockholm, Sweden, July 5, 2022 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's second quarter report for April - June 2022 on Tuesday, July 12, 2022, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on July 12, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the second quarter report for April - June 2022, followed by a Q&A-session.
To attend, please dial-in at one of the numbers below, from:
Sweden: +46 8 505 163 86, Pin code: 4533870#
UK: +44 203 198 4884, Pin code: 4533870#
US: +1 412 317 6300, Pin code: 4533870#
The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.se/en/section/investors/presentations/ after the presentation.
For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations, BioArctic AB
Tel: + 46 704 10 71 80
This information was submitted for publication at 08:00 a.m. CET on July 5, 2022.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.